TEVA-LATANOPROST SOLUTION

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

LATANOPROST

Commercializzato da:

TEVA CANADA LIMITED

Codice ATC:

S01EE01

INN (Nome Internazionale):

LATANOPROST

Dosaggio:

50MCG

Forma farmaceutica:

SOLUTION

Composizione:

LATANOPROST 50MCG

Via di somministrazione:

OPHTHALMIC

Confezione:

2.5ML

Tipo di ricetta:

Prescription

Area terapeutica:

PROSTAGLANDIN ANALOGS

Dettagli prodotto:

Active ingredient group (AIG) number: 0132916002; AHFS:

Stato dell'autorizzazione:

CANCELLED PRE MARKET

Data dell'autorizzazione:

2015-10-16

Scheda tecnica

_TEVA-LATANOPROST Product Monograph _
1
PRODUCT MONOGRAPH
PR
TEVA-LATANOPROST
Latanoprost Ophthalmic Solution
50 mcg/mL
Prostaglandin F
2α
Analogue
TEVA CANADA LIMITED
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Revision:
November 27, 2018
CONTROL NUMBER: 221815
_TEVA-LATANOPROST Product Monograph _
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
3
ADVERSE REACTIONS
...........................................................................................................
6
DRUG INTERACTIONS
............................................................................................................
7
DOSAGE AND ADMINISTRATION
........................................................................................
8
OVERDOSAGE
..........................................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
9
STORAGE AND STABILITY
.................................................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 10
PART II: SCIENTIFIC INFORMATION
...............................................................................
11
PHARMACEUTICAL INFORMATION
.................................................................................
11
CLINICAL STUDIES
...............................................................................................................
12
DETAILED PHARMACOLOGY
.............................................